Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06861088 · ClinicalTrials.gov registry record · Phase 3
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
A Phase 3 study of Venous Thromboembolism and Metastatic Pancreatic Cancer, sponsored by Quercis Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 3
- Study locations
NCT06861088 is a Phase 3 study of Venous Thromboembolism and Metastatic Pancreatic Cancer that is actively recruiting participants, run by Quercis Pharma. The registered enrollment target is 480 participants, below the 6,286-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06861088, a Phase 3 study of Venous Thromboembolism and Metastatic Pancreatic Cancer, is actively recruiting participants, sponsored by Quercis Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 3
- Study locations
Study Summary
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Kinisoquin™
Study Locations (3)
California
- Ventura Clinical Trials - Ventura
Florida
- Clavis Medical, LLC - Miami Lakes
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2029-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06861088
The ClinicalTrials.gov registry entry for NCT06861088 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,286-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (92% lower). The listed sponsor is Quercis Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06861088 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06861088 about?
NCT06861088 is a clinical study titled "The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer". The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
What is the current status of trial NCT06861088?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-12-19. Estimated completion is 2029-10-31.
What conditions does trial NCT06861088 study?
This clinical trial studies the following conditions: Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT06861088?
The interventions under investigation include: Placebo (DRUG), Kinisoquin™ (DRUG).
Who is sponsoring clinical trial NCT06861088?
This trial is sponsored by Quercis Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06861088 being conducted?
This trial has 3 study locations across California, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
COMPLETED · Phase 3
-
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
COMPLETED · Phase 3
-
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
COMPLETED · Phase 3
-
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
COMPLETED · Phase 3
-
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.